This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Anti GAD

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Anti-glutamic acid decarboxylase (GAD) antibodies have been associated with type 1 diabetes mellitus and a large variety of neurological conditions, including epilepsy (1).

GAD antibodies are also associated with other conditions such as Stiff Man syndrome.

The background frequency of anti-GAD antibodies in the general population has been assessed to be around 0.4-1% (2)


  • Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008;131:2553-63
  • Batstra MR, van Driel A, Petersen JS, et al. Glutamic acid decarboxylase antibodies in screening for autoimmune diabetes: influence of comorbidity, age, and sex on specificity and threshold values. Clin Chem 1999;45:2269-72.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page